UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

~~November 3~~December 16, 2023

Aridis Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-38630		47-2641188
(State or other jurisdiction of incorporation)		(Commission File Number)		(I. R. S. Employer Identification No.)

983 University Avenue, Bldg. B

Los Gatos, California 95032

(Address of principal executive offices, including ZIP code)

(408) 385-1742

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class: Trading Symbol(s) Name of each exchange on which registered: Common Stock ARDS ~~Nasdaq~~OTC ~~Capital Market~~QB

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 25.0203 ~~Results~~Amendments to Articles of ~~Operations~~Incorporation ~~and~~or ~~Financial~~Bylaws; ~~Condition~~Change in Fiscal Year.

On December ~~November 3~~16, 2023, the Board of Directors of Aridis Pharmaceuticals, Inc. ~~issued~~(the a“Company”) ~~press~~approved ~~release~~an ~~announcing~~amendment ~~financial~~of ~~and~~the ~~corporate~~Company’s Bylaws ~~results~~(the ~~for~~“Bylaws”) to change the quorum for stockholder meetings to equal one-third ~~quarter~~(33.33%) ~~ended~~of the shares issued and ~~September~~outstanding ~~30,~~and ~~2023~~entitled to vote on the matters at the meeting. AThe ~~copy~~change ofto the ~~press~~quorum ~~release~~requirement isfor ~~furnished~~stockholder asmeetings ~~Exhibit~~was ~~99.1~~made to improve the Company’s ability to ~~this~~hold ~~Form~~stockholder ~~8-K~~meetings when called.

The ~~information disclosed under~~ ~~this~~foregoing ~~Item~~description ~~2.02,~~of ~~including~~the ~~Exhibit~~amendment ~~99.1 hereto,~~ is ~~being~~qualified ~~furnished~~in ~~and~~its ~~shall~~entirety ~~not~~by bereference ~~deemed~~to ~~“filed”~~the ~~for~~full ~~purposes~~text of ~~Section 18 of~~ the ~~Securities~~Amendment ~~Exchange~~to ~~Act~~the ~~of 1934~~Company’s Bylaws, aswhich ~~amended,~~is ~~nor~~filed ~~shall~~as itExhibit be3.1 ~~incorporated by reference into any registration statement or other document pursuant~~ to ~~the~~this ~~Securities~~Current ~~Act~~Report ofon ~~1933,~~Form as8-K ~~amended,~~and ~~except~~is asincorporated ~~expressly~~by ~~set~~reference ~~forth in such filing~~herein.

Item 9.01.

Financial Statements and Exhibits

(d) Exhibits.

99.1	Press Release of Aridis Pharmaceuticals, Inc. dated November 3, 2023
3.1	Amendment to Bylaws of Aridis Pharmaceuticals, Inc.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 3, 2023	ARIDIS PHARMACEUTICALS, INC.
Date: December 18, 2023	ARIDIS PHARMACEUTICALS, INC.
	/s/ Vu Truong
	Vu Truong
	Chief Executive Officer

-3-

Filing Compare · Aridis Pharmaceuticals, Inc.